IDEXX Laboratories (FRA:IX1) Short-Term Debt: €588 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IX1 IDEXX Laboratories Inc FRA:IX1
96 GF Score
Price €492.80
GF Value €577.54
Valuation Modestly Undervalued
View Full Analysis

What is IDEXX Laboratories Short-Term Debt?

IDEXX Laboratories FRA:IX1 +0.47% 96 Short-Term Debt is €588 Mil as of Mar. 2026. GuruFocus rates FRA:IX1 with a GF Score™ of 96/100 and a GF Value™ of €577.54 (Modestly Undervalued).

IDEXX Laboratories's Short-Term Debt for the quarter that ended in Mar. 2026 was €588 Mil.

IDEXX Laboratories's quarterly Short-Term Debt declined from Sep. 2025 (€515 Mil) to Dec. 2025 (€404 Mil) but then increased from Dec. 2025 (€404 Mil) to Mar. 2026 (€588 Mil).

IDEXX Laboratories's annual Short-Term Debt increased from Dec. 2023 (€298 Mil) to Dec. 2024 (€399 Mil) and increased from Dec. 2024 (€399 Mil) to Dec. 2025 (€404 Mil).

IDEXX Laboratories Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

IDEXX Laboratories Short-Term Debt Related Terms

IDEXX Laboratories Short-Term Debt Historical Data

* Premium members only.

The historical data trend for IDEXX Laboratories's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDEXX Laboratories Short-Term Debt Chart

IDEXX Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 131.42 617.36 298.02 398.99 403.94

IDEXX Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 453.65 567.01 515.46 403.94 588.20
FRA:IX1
96GF Score
IDEXX Laboratories Inc FRA:IX1
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €588 Mil mean?
IDEXX Laboratories (FRA:IX1) has a Short-Term Debt of €588 Mil as of Mar. 2026.
Is IDEXX Laboratories' Short-Term Debt too high?
IDEXX Laboratories' current Short-Term Debt is €588 Mil. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Short-Term Debt compare to A and NTRA?
IDEXX Laboratories' Short-Term Debt of €588 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Diagnostics & Research company?
A good Short-Term Debt depends on the Medical Diagnostics & Research industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. IDEXX Laboratories's current Short-Term Debt is €588 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €577.54, compared to a current price of €492.80 — trading 14.7% below its estimated fair value. The current Short-Term Debt is €588 Mil. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current Short-Term Debt is €588 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?

Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued. The current stock price of €492.80 is trading 14.7% below its estimated GF Value™ of €577.54. GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.

Key valuation signals for FRA:IX1:

  • Short-Term Debt: €588 Mil
  • GF Value™: €577.54 vs. price of €492.80 (14.7% below fair value)
  • GF Score™: 96/100

No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IDEXX Laboratories Business Description

Address One IDEXX Drive, Westbrook, ME, USA, 04092
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score

Get the complete analysis for FRA:IX1

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€492.80
Price
€577.54
GF Value